The incidence of CK-MB and cTnI elevation in the rosuvastatin group was significantly lower compared with the control group (0.7% vs. 11.0%, p<0.001 and 10.5% vs. 39.0%, p<0.001, respectively), and Cay indicated that high loading dose of rosuvastatin (40 mg/day) could effectively reduce the incidence of peri-procedural myocardial necrosis and infarction. Here, TNNI3 is linked to infarction.